Recombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission.

2.50
Hdl Handle:
http://hdl.handle.net/10541/92034
Title:
Recombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission.
Authors:
Kasper, Christoph; Schwarzer, A; De Wynter, Erika A; Chang, James; Dexter, T Michael; Ryder, W David J; Testa, Nydia G
Abstract:
The megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.
Affiliation:
Cancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, UK.
Citation:
Recombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission. 1998, 12 (6):907-11 Leukemia
Journal:
Leukemia
Issue Date:
Jun-1998
URI:
http://hdl.handle.net/10541/92034
PubMed ID:
9639419
Type:
Article
Language:
en
ISSN:
0887-6924
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorKasper, Christophen
dc.contributor.authorSchwarzer, Aen
dc.contributor.authorDe Wynter, Erika Aen
dc.contributor.authorChang, Jamesen
dc.contributor.authorDexter, T Michaelen
dc.contributor.authorRyder, W David Jen
dc.contributor.authorTesta, Nydia Gen
dc.date.accessioned2010-02-12T16:09:26Z-
dc.date.available2010-02-12T16:09:26Z-
dc.date.issued1998-06-
dc.identifier.citationRecombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission. 1998, 12 (6):907-11 Leukemiaen
dc.identifier.issn0887-6924-
dc.identifier.pmid9639419-
dc.identifier.urihttp://hdl.handle.net/10541/92034-
dc.description.abstractThe megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.en
dc.language.isoenen
dc.subjectHaematopoiesisen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectAcute Myeloid Leukaemiaen
dc.subjectCancer Proteinsen
dc.subject.meshAdult-
dc.subject.meshBone Marrow Cells-
dc.subject.meshCell Count-
dc.subject.meshCulture Techniques-
dc.subject.meshFemale-
dc.subject.meshHematopoiesis-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Myeloid, Acute-
dc.subject.meshMale-
dc.subject.meshMegakaryocytes-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshProto-Oncogene Proteins-
dc.subject.meshReceptors, Cytokine-
dc.subject.meshReceptors, Thrombopoietin-
dc.subject.meshRecombinant Proteins-
dc.subject.meshReference Values-
dc.titleRecombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalLeukemiaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.